# Nippon Shinyaku Co.,Ltd.: business model and financials

> Latest period: FY ending Mar 2024, consolidated, IFRS
> Unit: JPY millions
> Sources: 有価証券報告書－第163期(2025/04/01－2026/03/31) (S100YGRG)
> Page: https://vizora.meequs.com/en/company/nippon-shinyaku
> Retrieved: 2026-09-30T22:47:46.368Z

## Company

Nippon Shinyaku is a company in Pharmaceuticals listed on TSE Prime. It has 2,213 employees (consolidated).

| Field | Value |
| --- | ---: |
| Legal name | Nippon Shinyaku Co., Ltd. |
| Ticker | 4516 |
| Stock price | View on Yahoo Finance (https://finance.yahoo.co.jp/quote/4516.T) |
| Listing | TSE Prime |
| Head office | 京都市南区吉祥院西ノ庄門口町14番地 |
| Representative (per filing) | 代表取締役社長 中井 亨 |
| Employees (consolidated) | 2,213 |
| Fiscal year end | March |
| Website | www.nippon-shinyaku.co.jp (https://www.nippon-shinyaku.co.jp/) |
| Corporate number | 2130001012236 |
| EDINET | E00931 |
| Industries (Vizora) | Pharmaceuticals |

> Profile source: annual securities report (S100YGRG, filed 2026-06-23). As of filing

## Five-axis industry profile

Primary industry: Pharmaceuticals (2024-03-31)

| Axis | Industry percentile | Peers |
| --- | ---: | ---: |
| Efficiency | 67.2 | 32 |

Each axis is shown independently. Missing values are labeled unavailable; no combined score is calculated. Industry rank is not an investment recommendation.

## Key points (generated from figures)

- Nippon Shinyaku brought in ¥148.3B in revenue.
- Revenue changed +2.8% from the prior year.

## Key figures at a glance

| Metric | Value | Note |
| --- | ---: | ---: |
| Revenue | ¥148.3B |  |
| Operating income | — | Margin — |
| Net income | ¥25.9B | Margin 17.4% |
| Free cash flow | — |  |
| Employees (consolidated) | 2,213 |  |
| Cash ratio | 22.1% | Cash ÷ revenue 39.2% |
| ROE | 11.7% | Equity approximated |
| ROA | 10.3% | Derived from disclosed figures |

## What changed in 4 years

| Metric | FY ending Mar 2020 | FY ending Mar 2024 | Change |
| --- | ---: | ---: | ---: |
| Revenue | ¥116637000000 | ¥148255000000 | +27.1% |
| Employees | 2,026 people | 2,213 people | +9.2% |
| Cash and equivalents | ¥43583000000 | ¥58094000000 | +33.3% |

### Change in segment revenue mix

Span: FY ending Mar 2020 → FY ending Mar 2024. Stable segment keys are connected; unmatched shares are marked as new or reorganized. Shares use total segment revenue.

| Flow | Revenue share |
| --- | ---: |
| 医薬品 → 事業再編・廃止 | 87.1% |
| 機能食品 → 事業再編・廃止 | 12.9% |

Segment revenue source references: 2 (derived)

## Income statement（FY ending Mar 2024, consolidated, IFRS）

| Item | Amount (JPY mn) | % of revenue | Source |
| --- | ---: | ---: | ---: |
| Revenue | 148,255 | 100.0% | S100YGRG |
| Pretax income | 33,616 | 22.7% | S100YGRG |
| Net income attributable to owners | 25,851 | 17.4% | S100YGRG |

A machine-readable operating income value exists, but it is not in the validated published data, so the chart is omitted.

## Year over year（FY ending Mar 2023 → FY ending Mar 2024、JPY mn）

| Metric | Prior | Current | Change | % change |
| --- | ---: | ---: | ---: | ---: |
| Revenue | 144,175 | 148,255 | 4,080 | +2.8% |
| Net income attributable to owners | 22,812 | 25,851 | 3,039 | +13.3% |
| Operating cash flow | 26,170 | 16,289 | -9,881 | -37.8% |

## History（JPY mn）

| Period | Revenue | Op. income | Op. margin | Net income | Op. CF | FCF | Source |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| FY ending Mar 2020 | 116,637 | 21,668 | 18.6% | 16,866 | 12,737 | 10,920 | S100LX4O |
| FY ending Mar 2022 | 137,484 | — | — | 24,986 | 21,316 | — | S100YGRG |
| FY ending Mar 2023 | 144,175 | — | — | 22,812 | 26,170 | — | S100YGRG |
| FY ending Mar 2024 | 148,255 | — | — | 25,851 | 16,289 | — | S100YGRG |

## People and productivity（FY ending Mar 2024, consolidated, IFRS）

| Metric | Value |
| --- | ---: |
| Revenue per employee (consolidated) | ¥67M |
| Net income per employee (consolidated) | ¥11.7M |

Employees, revenue and profit are consolidated. Average annual salary is a separate parent-company figure. Calculated from disclosed figures (DERIVED).

| History | FY ending Mar 2020 | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 |
| --- | ---: | ---: | ---: | ---: |
| Employees (consolidated) | 2,026 | 2,125 | 2,186 | 2,213 |
| Average salary (parent company) | — | — | — | — |
| Average age (parent company) | — | — | — | — |
| Average tenure (parent company) | — | — | — | — |

Year over year: Employees (consolidated) +1.2% · Revenue (consolidated) +2.8%

## Revenue by geography

No geographic revenue breakdown was disclosed.

## Cash flow（FY ending Mar 2024, consolidated, IFRS）

| Item | Amount (JPY mn) | % of revenue | Source |
| --- | ---: | ---: | ---: |
| Operating cash flow | 16,289 | 11.0% | S100YGRG |
| Investing cash flow | -9,921 | -6.7% | S100YGRG |
| Financing cash flow | -9,719 | -6.6% | S100YGRG |
| Change in cash | -3,351 | -2.3% | 算出 |
| Cash and equivalents | 58,094 | 39.2% | S100YGRG |

## Balance sheet

Figures are as of each fiscal year end. Derived values are marked as such in the source column. Lease liabilities are excluded from interest-bearing debt.

| Metric | FY ending Mar 2020 | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | Source |
| --- | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | 43,583 | 60,566 | 60,047 | 58,094 | S100OM32, S100YGRG |
| Total assets | 181,533 | 219,943 | 237,451 | 263,404 | S100OM32, S100YGRG |
| Net assets | 146,861 | 176,767 | — | 220,534 | S100OM32, S100YGRG |
| Share capital | 5,174 | — | — | — | S100OM32 |
| Trade receivables | 40,947 | — | — | — | S100LX4O |
| Property, plant and equipment | 26,110 | — | — | — | S100OM32 |
| Intangible assets excluding goodwill | 546 | — | — | — | S100LX4O |
| Investment securities | 18,909 | — | — | — | S100LX4O |
| Current assets | 120,798 | — | — | — | S100OM32 |
| Current liabilities | 24,965 | — | — | — | S100LX4O |
| Trade payables | 11,213 | — | — | — | S100LX4O |
| Total liabilities | 34,671 | — | — | — | S100OM32 |
| Non-controlling interests | 269 | — | — | — | S100LX4O |
| Equity attributable to owners of parent | 146,592 | — | — | — | S100OM32 |
| Retained earnings | 132,111 | — | — | — | S100OM32 |
| Treasury stock | -2,473 | — | — | — | S100OM32 |

### Balance sheet history

| Metric | FY ending Mar 2020 | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 |
| --- | ---: | ---: | ---: | ---: |
| Total assets | 181,533 | 219,943 | 237,451 | 263,404 |
| Equity | 146,861 | 176,767 | — | 220,534 |
| Interest-bearing debt | — | — | — | — |
| Cash | 43,583 | 60,566 | 60,047 | 58,094 |

### Cash quality

Net cash = cash − interest-bearing debt. Net debt ratio = (interest-bearing debt − cash) ÷ positive operating cash flow. Omit when debt components are incomplete; other ratios are derived from reported figures.

| Metric | Value |
| --- | ---: |
| Cash ratio (cash ÷ total assets) | 22.1% |
| Cash ÷ revenue | 39.2% |
| Net cash (cash − interest-bearing debt) | — |
| Net debt ÷ operating cash flow | — |
| Cash conversion (operating CF ÷ operating income) | — |
| Cash vs. profit gap | -9,562 JPY mn (of net income -37.0%) |
| Shareholder returns / net income | — |
| Shareholder returns / FCF | — |
| Shareholder payments — dividends / net income | — |
| Shareholder payments — dividends / FCF | — |
| CapEx intensity (capex ÷ revenue) | — |
| Investing CF relative to operating CF | 60.9% |

## ROA and ROE

ROE is decomposed into net margin × asset turnover × financial leverage. Leverage can raise ROE, so the ratio alone does not assess a company's condition. Ending balances are used without a prior year; total equity approximates parent equity when unavailable.

| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE | Sources |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| 2020 | 14.5% | 0.64× | 9.3% | 1.24× | 11.5% | S100LX4O, S100OM32 |
| 2022 | 18.2% | 0.63× | 11.4% | 1.24× | 14.1% | S100YGRG |
| 2023 | — | —× | 10.0% | —× | — | S100YGRG |
| 2024 | 17.4% | 0.59× | 10.3% | 1.14× | 11.7% | S100YGRG |

## Ownership

| Counterparty | Relation | Ratio | As of |
| --- | ---: | ---: | ---: |
| 日本マスタートラスト信託銀行株式会社（信託口） | Major shareholder | 12.0% | 2026-03-31 |
| 明治安田生命保険相互会社 | Major shareholder | 9.6% | 2026-03-31 |
| 株式会社日本カストディ銀行（信託口） | Major shareholder | 7.3% | 2026-03-31 |
| 株式会社京都銀行 | Major shareholder | 4.6% | 2026-03-31 |
| 株式会社三菱ＵＦＪ銀行 | Major shareholder | 4.0% | 2026-03-31 |
| 日本生命保険相互会社 | Major shareholder | 2.0% | 2026-03-31 |
| ＳＴＡＴＥ ＳＴＲＥＥＴ ＢＡＮＫ ＡＮＤ ＴＲＵＳＴ ＣＯＭＰＡＮＹ ５０５００１（常任代理人 株式会社みずほ銀行決済営業部） | Major shareholder | 1.9% | 2026-03-31 |
| ＴＨＥ ＢＡＮＫ ＯＦ ＮＥＷ ＹＯＲＫ ＭＥＬＬＯＮ １４００４４（常任代理人 株式会社みずほ銀行決済営業部） | Major shareholder | 1.7% | 2026-03-31 |
| モルガン・スタンレーＭＵＦＧ証券株式会社 | Major shareholder | 1.7% | 2026-03-31 |
| ＳＴＡＴＥ ＳＴＲＥＥＴ ＢＡＮＫ ＡＮＤ ＴＲＵＳＴ ＣＯＭＰＡＮＹ ５０５１０３（常任代理人 株式会社みずほ銀行決済営業部） | Major shareholder | 1.7% | 2026-03-31 |

## Sources

| Document | ID | Published | URL |
| --- | ---: | ---: | ---: |
| 有価証券報告書－第163期(2025/04/01－2026/03/31) | S100YGRG | 2026-06-23 | https://disclosure2.edinet-fsa.go.jp/WZEK0040.aspx?S100YGRG,, |
| 有価証券報告書－第161期(2023/04/01－2024/03/31) | S100TXM6 | 2024-06-28 | https://disclosure2.edinet-fsa.go.jp/WZEK0040.aspx?S100TXM6,, |
| 有価証券報告書－第159期(令和3年4月1日－令和4年3月31日) | S100OM32 | 2022-06-30 | https://disclosure2.edinet-fsa.go.jp/WZEK0040.aspx?S100OM32,, |
| 訂正有価証券報告書－第158期(令和2年4月1日－令和3年3月31日) | S100LX4O | 2021-07-02 | https://disclosure2.edinet-fsa.go.jp/WZEK0040.aspx?S100LX4O,, |

## Definitions

- Amounts are in millions of JPY (rounded). The period is stated in each table heading
- Operating margin = operating income ÷ revenue. Net income is attributable to owners of the parent when disclosed
- Free cash flow (FCF) = operating cash flow − capital expenditure
- ¥100 model = breakdown per ¥100 of revenue (rounded so parts sum to 100)
- Segment revenues include inter-segment sales and may not sum to consolidated revenue
- Source IDs are EDINET document IDs (docID). "算出" (derived) means computed from other disclosed values
- All figures are extracted mechanically from filings. AI-written text never generates figures
- Source: company filings submitted to EDINET (Financial Services Agency of Japan). Figures were extracted, edited and processed, and charts and text were created, by Vizora — not by the FSA (used under the Public Data License v1.0).